Neurocrine Biosciences, Inc. (NBIX)

Market Cap	13.53B
Revenue (ttm)	1.89B
Net Income (ttm)	249.70M
Shares Out	99.51M
EPS (ttm)	2.47
PE Ratio	55.06
Forward PE	27.82
Dividend	n/a
Ex-Dividend Date	n/a

Volume	698,464
Open	137.47
Previous Close	137.76
Day's Range	135.17 - 138.63
52-Week Range	89.04 - 148.37
Beta	0.28
Analysts	Buy
Price Target	142.71 (+4.94%)
Earnings Date	May 1, 2024

About NBIX

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to trea...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 23, 1996
• Employees: 1,400
• Stock Exchange: NASDAQ
• Ticker Symbol: NBIX

Financial Performance

In 2023, NBIX's revenue was $1.89 billion, an increase of 26.76% compared to the previous year's $1.49 billion. Earnings were $249.70 million, an increase of 61.62%.

Analyst Forecast

According to 22 analysts, the average rating for NBIX stock is "Buy." The 12-month stock price forecast is $142.71, which is an increase of 4.94% from the latest price.

Price Target

$142.71

(4.94% upside)

Analyst Consensus: Buy